Navigation Links
Vista Partners Initiates Coverage on Synvista Therapeutics, Inc. (AMEX: SYI)
Date:5/14/2008

LOS ANGELES, May 14 /PRNewswire/ -- Vista Partners announced today that it has initiated coverage on Synvista Therapeutics, Inc. (Amex: SYI). Ross Silver, Director of Research of Vista Partners stated, "Synvista is one of the best small cap investment opportunities investors will come across. The company is conducting four Phase 2 trials in multi-billion dollar markets. Additionally their Hp test which will serve a ~$100M market, could begin to produce revenues as early as next year. It is also important to note that Synvista is led by a top tier management team who has taken compounds from concept to approval, a feat few management teams in small cap biotech have achieved." To view the report on Synvista at no charge, please visit the Vista Partners website at http://www.vistap.com and click on the download research icon located on top right hand corner of the home page.

About Vista Partners:

Vista Partners provides independent, equity research to institutional and individual investors, with a focus on publicly traded small capitalization companies. With offices in Los Angeles and San Francisco, Vista Partners is one of the fastest growing independently owned equity research firms. Vista Partners professional staff has backgrounds in finance, corporate communications and investment banking. More information is available at http://www.vistap.com.

About Synvista Therapeutics, Inc.:

Synvista Therapeutics, Inc. is a product-based biotechnology company engaged in the development of diagnostic tests and drugs to identify and treat diabetic patients at high risk for the development of cardiovascular disease. The Company has identified several promising product candidates that it believes represent novel approaches for diagnosis and treatment in some of the largest pharmaceutical markets. Currently, Synvista is advancing the development and commercialization of a diagnostic product and conducting Phase 2 clinical trials for two of its other drug candidates. For more information, please visit the Company's website at http://www.synvista.com.

Contact:

Vista Partners LLC

Ross Silver

(310) 744-5268

info@vistap.com

http://www.vistap.com


'/>"/>
SOURCE Vista Partners
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Expiry of Hart-Scott-Rodino Waiting Period for JUVISTA(R) (Human TGF BETA 3)
2. OncoVista, Inc. Closes on $6.8 Million Financing and Acquires Control of a Public Shell Company
3. Synvista Therapeutics to Present at the BIO InvestorForum 2007
4. Synvista Therapeutics to be Featured on Wallst.net
5. Provista Awards Agreement to Spheris
6. Synvista Therapeutics to Develop Topical Formulation of ALT-2074 for the Treatment of Psoriasis
7. Synvista Therapeutics to Present at the 10th Annual BIO CEO & Investor Conference
8. Renovo Announces Results of Latest Phase 2 Studies of JUVISTA(R) (Human Recombinant TGFbeta3)
9. Vista Partners Updates Coverage on Inovio Biomedical Corporation (Amex: INO) With $3.52 Price Target
10. Synvista Therapeutics Highlights Newly Published Data Demonstrating the Value of Haptoglobin Genotype Testing In People with Diabetes
11. Bayer HealthCare Pharmaceuticals Introduces VistaTrak(TM) an Innovative Contrast Media Management System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... March 29, 2017 /PRNewswire/ - The University of Missouri ... a business of Sterigenics International, and General Atomics (GA), ... submitted to the U.S. Nuclear Regulatory Commission (NRC). This ... of molybdenum-99 (Mo-99). Once operational, production from this facility ... demand for Mo-99, which currently must be imported from ...
(Date:3/28/2017)... ... March 28, 2017 , ... Today, ... Advancement of Science (AAAS), the world's largest general scientific society and publisher ... scholarly collection across its cross-platform reference management system. , All six Science-branded ...
(Date:3/28/2017)... , ... March 28, 2017 , ... ... a Marketing Roundtable on March 22 in Philadelphia. The event was offered by ... The Marketing Roundtable featured breakout groups and interaction with speakers who ...
(Date:3/28/2017)... N.J. and WASHINGTON , ... genomics service provider, GENEWIZ, will launch single-cell sequencing during the ... the Walter E. Washington Convention Center in ... allows researchers to perform differential gene expression of thousands ... Highlights: Experts on-hand ...
Breaking Biology Technology:
(Date:3/27/2017)... CENTRE, N.Y. , March 27, 2017 /PRNewswire-USNewswire/ ... Healthcare Information and Management Systems Society (HIMSS) Analytics ... Outpatient EMR Adoption Model sm . In addition, ... 12% of U.S. hospitals using an electronic medical ... CHS for its high level of EMR usage ...
(Date:3/22/2017)... 2017   Neurotechnology , a provider of ... announced the release of the SentiVeillance 6.0 ... facial recognition using up to 10 surveillance, security ... The new version uses deep neural-network-based facial detection ... utilizes a Graphing Processing Unit (GPU) for enhanced ...
(Date:3/16/2017)... 2017 - Against identity fraud with DERMALOG solutions "Made in Germany "  ... ... project, multi-biometric solutions provide a crucial contribution against identity fraud. (PRNewsFoto/Dermalog Identification Systems) ... Used combined in one project, multi-biometric solutions provide a crucial contribution against ... ...
Breaking Biology News(10 mins):